List of Excipients in Branded Drug RELPAX

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ROERIG	RELPAX	eletriptan hydrobromide	0049-2330	ALUMINUM OXIDE
ROERIG	RELPAX	eletriptan hydrobromide	0049-2330	CELLULOSE, MICROCRYSTALLINE
ROERIG	RELPAX	eletriptan hydrobromide	0049-2330	CROSCARMELLOSE SODIUM
ROERIG	RELPAX	eletriptan hydrobromide	0049-2330	FD&C YELLOW NO. 6
ROERIG	RELPAX	eletriptan hydrobromide	0049-2330	HYPROMELLOSE
ROERIG	RELPAX	eletriptan hydrobromide	0049-2330	LACTOSE MONOHYDRATE

Relpax Excipient Strategy and Commercial Opportunities for Eletriptan Tablets

Last updated: October 21, 2026

Relpax is the brand name for eletriptan hydrobromide, an oral 5-HT1B/1D agonist approved for the acute treatment of migraine with or without aura in adults. The commercial opportunity is primarily generic substitution and differentiated oral delivery, not protection of a new chemical entity. Relpax uses a conventional immediate-release, film-coated tablet with a relatively simple excipient system, creating low technical barriers for ANDA applicants but limited room for premium pricing [1].

What excipients are used in Relpax tablets?

Relpax 20 mg and 40 mg tablets use standard immediate-release tablet excipients. FDA labeling identifies the core formulation as containing lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The film coating contains hypromellose, titanium dioxide, triacetin, and colorants [1].

Formulation element	Relpax excipient or function	Commercial significance
Diluent	Lactose monohydrate	Supports tablet weight and compressibility; creates an opportunity for lactose-free alternatives
Binder and filler	Microcrystalline cellulose	Improves compaction and tablet mechanical strength
Disintegrant	Croscarmellose sodium	Promotes tablet breakup and immediate release
Lubricant	Magnesium stearate	Reduces sticking and ejection force; excessive levels can slow dissolution
Film former	Hypromellose	Provides coating integrity and swallowability
Plasticizer	Triacetin	Improves coating flexibility
Opacifier	Titanium dioxide	Controls appearance and light protection
Colorants	FDA-permitted color additives	Supports product identification and brand differentiation

The label does not indicate a modified-release system, enteric coating, osmotic delivery mechanism, or complex multiparticulate technology. The target product is therefore a conventional immediate-release oral tablet rather than a formulation with substantial device or manufacturing complexity [1].

What is the role of each excipient?

Eletriptan hydrobromide is delivered at relatively low active-drug strength. The 20 mg and 40 mg strengths require excipients to provide tablet bulk, dose uniformity, rapid disintegration, and acceptable coating performance.

Lactose monohydrate is commercially efficient but excludes patients with certain excipient preferences, including some consumers seeking lactose-free products. Microcrystalline cellulose can replace much of the diluent and compression function, although a lactose-free formulation may require changes to flow, compactability, tablet weight, and dissolution.

Croscarmellose sodium is central to rapid disintegration. Its level, grade, and incorporation method can affect dissolution performance. Magnesium stearate requires control because excessive lubrication can reduce wetting and delay drug release.

The film coat has limited pharmacokinetic importance but matters for tablet robustness, appearance, swallowing, and product identification. A generic manufacturer can generally use a different film-coating composition if the finished product meets pharmaceutical quality and bioequivalence requirements.

What commercial opportunities exist for Relpax excipient reformulation?

The strongest opportunities are low-cost generic manufacturing, excipient substitution, and patient-segment differentiation. A reformulation must preserve immediate release and demonstrate comparable exposure and dissolution to the reference product.

Lactose-free eletriptan tablets

The most direct excipient opportunity is replacing lactose monohydrate with a lactose-free filler system. Potential alternatives include:

• Microcrystalline cellulose at a higher proportion
• Mannitol
• Dibasic calcium phosphate
• Pregelatinized starch
• Coprocessed filler systems

Mannitol can improve mouthfeel and provide a differentiated sensory profile, but it may increase tablet size or alter compression behavior. Dibasic calcium phosphate supports robust compaction but may require careful control of disintegration and compatibility. Starch-based systems can improve disintegration but may affect moisture sensitivity and powder flow.

A lactose-free claim could support pharmacy and consumer segmentation, but it would not automatically create patent protection. The commercial value would depend on labeling, manufacturing cost, supply reliability, and whether the product is sold through retail, mail-order, or specialty pharmacy channels.

Low-cost, high-throughput generic tablets

Relpax’s standard tablet design is suitable for high-volume direct compression or conventional wet granulation. A manufacturer can target:

• Reduced tablet manufacturing cost
• Fewer processing steps
• Lower coating weight
• Improved tablet hardness
• More efficient packaging
• Dual-source excipient procurement

The key technical controls are blend uniformity, lubrication time, tablet weight, hardness, friability, disintegration, dissolution, assay, and degradation products. Because eletriptan is administered at 20 mg or 40 mg, content uniformity remains important even though the active ingredient is not present at trace-level concentration.

Small-volume or orally disintegrating products

An orally disintegrating tablet, orally dispersible tablet, or fast-dissolving dosage form could target patients who have nausea, difficulty swallowing, or limited access to water during migraine attacks. Suitable excipients may include mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and taste-masking agents.

The commercial risk is higher than for a standard tablet. Eletriptan has a bitter active ingredient, and taste masking can require coating, complexation, ion exchange, or polymeric barrier technologies. An orally disintegrating product may also be regulated as a new dosage form requiring a 505(b)(2) application rather than a simple ANDA, depending on the reference product and formulation claims.

What formulation patents protect Relpax?

The original Relpax product was protected principally by patents directed to eletriptan and related pharmaceutical compositions rather than by a complex excipient platform. Public FDA Orange Book materials should be used to verify the current listing status and expiration of any patents associated with the reference product [2].

The commercial position has changed materially because eletriptan generic products have entered the U.S. market. That indicates that the principal small-molecule and product-specific barriers have expired, been overcome, or no longer prevent ANDA approval.

A generic formulation does not need to copy the branded excipient system. It must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA requirements. Excipients can differ if they do not alter safety, efficacy, dissolution, absorption, or product performance.

Are there active excipient patents for Relpax?

No widely recognized Relpax commercial barrier depends on an exclusive lactose, microcrystalline cellulose, croscarmellose sodium, or film-coating composition. These are commodity pharmaceutical excipients with extensive prior art and multiple suppliers.

A company could seek patents on a differentiated eletriptan formulation involving:

• A specific taste-masking matrix
• A rapidly disintegrating tablet with defined dissolution limits
• A moisture-protective coating
• A particle-size or solid-state composition
• A sublingual or buccal delivery system
• A combination product
• A manufacturing process that improves content uniformity or stability

Such claims would need meaningful technical distinctions and defensible patentability. A simple substitution of lactose with mannitol or microcrystalline cellulose would generally face obviousness and lack-of-inventive-step challenges.

When did Relpax lose market exclusivity?

Relpax was approved by FDA in December 2002 for acute migraine treatment in adults [1]. Its primary small-molecule exclusivity period ended years ago, and generic eletriptan products are commercially available in the United States.

Milestone	Date or status
FDA approval of Relpax	December 2002
Active ingredient	Eletriptan hydrobromide
Dosage form	Immediate-release film-coated tablet
Strengths	20 mg and 40 mg
Regulatory pathway for standard generics	ANDA
Current market structure	Brand plus generic eletriptan products
Biosimilar pathway	Not applicable
Primary commercial opportunity	Generic substitution and differentiated oral delivery

The exact patent expiration analysis should distinguish compound, formulation, method-of-use, pediatric, and regulatory exclusivity. Patent term adjustment or term extension can change the effective date for a particular patent. The Orange Book remains the controlling source for listed U.S. patents and exclusivity information [2].

What is the FDA regulatory status of generic eletriptan?

Generic eletriptan tablets are generally developed through the ANDA pathway. An applicant must show that the product has the same active ingredient, dosage form, route of administration, strength, and conditions of use as the reference listed drug, subject to FDA requirements.

For a conventional immediate-release tablet, the main development package normally includes:

1. Pharmaceutical equivalence.
2. Comparative dissolution.
3. Bioequivalence.
4. Stability data.
5. Manufacturing controls.
6. Impurity and degradation-product characterization.
7. Labeling that conforms to the reference product, subject to permitted differences.

A formulation using different excipients may still qualify for an ANDA. A product with a new route, materially different dosage form, or new clinical claim may require a 505(b)(2) application.

Which companies are challenging or competing with Relpax?

The competitive field includes the Relpax brand, generic eletriptan manufacturers, and other triptan products. Generic competition is broader than direct brand substitution because physicians and payers can choose among eletriptan, sumatriptan, rizatriptan, zolmitriptan, naratriptan, and related therapies.

Direct competitors

Direct competitors include manufacturers marketing eletriptan hydrobromide tablets in 20 mg and 40 mg strengths. FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, provides the authoritative list of approved generic products and therapeutic-equivalence evaluations [2].

Therapeutic competitors

Product	Active ingredient	Common commercial distinction
Relpax	Eletriptan	Branded eletriptan reference product
Generic eletriptan	Eletriptan hydrobromide	Lower-cost substitution
Imitrex and generics	Sumatriptan	Broad dosage-form and generic availability
Maxalt and generics	Rizatriptan	Orally disintegrating and tablet options
Zomig and generics	Zolmitriptan	Tablet and nasal delivery options
Amerge and generics	Naratriptan	Longer-acting triptan positioning

Eletriptan’s commercial differentiation depends on prescriber familiarity, payer formulary status, patient response, and generic acquisition cost. A new eletriptan formulation must compete against both generic tablets and alternative migraine delivery systems.

What generic entry risks exist for a new Relpax formulation?

The primary risk is price compression. A lactose-free or faster-disintegrating product may not command a durable premium if payers treat it as interchangeable with standard generic eletriptan.

Other risks include:

• Limited prescriber motivation to switch from low-cost generic tablets
• Difficulty proving meaningful clinical value from excipient changes alone
• Taste-masking costs for orally disintegrating products
• Higher packaging requirements for moisture-sensitive formulations
• Potential need for a 505(b)(2) application
• Lack of reimbursement for nonpreferred dosage forms
• Competing generic manufacturers with established supply contracts

The strongest commercial case is a targeted product with a clear use advantage, such as a genuinely water-free formulation for patients with migraine-associated nausea or a robust lactose-free product for institutional and pharmacy channels.

How strong is the Relpax patent estate?

The legacy Relpax patent estate has limited ability to block ordinary generic tablets because generic eletriptan products are already marketed. Patent strength is therefore more relevant to follow-on formulations than to the original immediate-release tablet.

Patent strategy	Likely barrier strength	Commercial assessment
Conventional lactose-free tablet	Low	Useful for product differentiation, weak exclusionary value
Alternative film coating	Low	Usually easy to design around
Orally disintegrating tablet	Moderate	Stronger if taste masking and dissolution are technically specific
Buccal or sublingual delivery	Moderate to high	May require clinical and regulatory investment
New combination product	Variable	Depends on clinical utility and claim breadth
Manufacturing process	Moderate	Valuable if it improves quality or lowers cost, but vulnerable to design-around
New chemical form of eletriptan	Potentially high	Requires strong solid-state and patent evidence

The most defensible intellectual-property strategy would combine formulation claims with process claims, stability claims, and carefully defined dissolution or pharmacokinetic performance. Broad excipient claims alone are unlikely to provide durable exclusivity.

What manufacturing and IP barriers affect eletriptan products?

Eletriptan manufacturing is less complex than biologic production or long-acting injectable development. The main barriers are formulation reproducibility, analytical control, supply-chain economics, and regulatory execution.

Important technical issues include:

• Control of active-particle size and polymorphic form
• Uniform distribution of eletriptan hydrobromide
• Lubrication control with magnesium stearate
• Rapid and reproducible disintegration
• Film-coat adhesion and color consistency
• Stability under heat and humidity
• Control of nitrosamine and other potentially mutagenic impurities where applicable
• Reliable supply of pharmaceutical-grade excipients

A company seeking a premium product must translate an excipient change into a measurable benefit. A lower tablet weight, better swallowing profile, faster dispersion, improved stability, or clear lactose-free positioning is more commercially relevant than an excipient change that has no visible patient or manufacturing benefit.

What licensing opportunities exist for Relpax-related products?

Licensing opportunities are more likely to involve commercial rights, manufacturing capacity, or differentiated delivery technology than access to the original Relpax intellectual property.

Potential transactions include:

• In-licensing an ANDA-ready eletriptan product
• Contract manufacturing of 20 mg and 40 mg tablets
• Regional commercialization of generic eletriptan
• Licensing an orally disintegrating or buccal platform
• Acquiring a dossier with established bioequivalence data
• Co-development of a lactose-free or low-allergen formulation
• Supply agreements for high-volume generic channels

The value of a licensing deal depends on regulatory status, approval geography, manufacturing cost, remaining market exclusivity, payer access, and the ability to differentiate from existing generic eletriptan products. A standard tablet dossier has limited strategic value unless it includes low-cost manufacturing, reliable supply, or meaningful geographic rights.

How does Relpax compare with competing migraine dosage forms?

Relpax is disadvantaged against products with more flexible administration options. Sumatriptan and rizatriptan have broad generic availability and multiple dosage forms. Nasal and injectable products can address patients who cannot tolerate oral tablets, while orally disintegrating products can reduce the need for water.

Relpax’s opportunity is strongest where an oral tablet remains clinically acceptable but the current formulation creates a manageable barrier, such as lactose content, swallowing difficulty, or packaging convenience. A new product should avoid competing solely on the claim that it contains a different excipient.

Key Takeaways

• Relpax contains a conventional immediate-release excipient system based on lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and a film coat.
• The original product is no longer protected by a meaningful market barrier against ordinary generic eletriptan tablets.
• The largest near-term opportunity is low-cost generic production, followed by lactose-free and orally disintegrating formulations.
• Excipient substitution alone is unlikely to support strong patent protection or premium pricing.
• A follow-on product needs a measurable benefit in administration, stability, dissolution, manufacturing cost, or patient usability.
• Biosimilar risk is irrelevant because eletriptan is a small-molecule drug, not a biologic.
• The Orange Book and FDA labeling remain the primary sources for current patent, exclusivity, reference-product, and therapeutic-equivalence status.

Frequently Asked Questions

Is Relpax lactose-free?

No. FDA labeling identifies lactose monohydrate as an inactive ingredient in Relpax tablets [1]. A generic manufacturer can develop a lactose-free eletriptan tablet if it satisfies FDA quality and bioequivalence requirements.

Can a generic eletriptan tablet use different excipients from Relpax?

Yes. An ANDA product may use different inactive ingredients if it remains pharmaceutically equivalent, bioequivalent, safe, stable, and acceptable under FDA requirements.

Is there a biosimilar version of Relpax?

No. Relpax contains eletriptan hydrobromide, a small molecule. Competitive products are generics approved through the ANDA pathway, not biosimilars.

Would an orally disintegrating eletriptan tablet require a new clinical trial?

The requirement depends on the formulation, route, claims, and regulatory pathway. A materially different dosage form may require a 505(b)(2) application and additional evidence beyond the standard ANDA package.

Can a new Relpax excipient formulation receive patent protection?

Potentially, but a patent would need claims directed to a non-obvious formulation, process, solid form, delivery system, or demonstrable performance advantage. A routine replacement of lactose with another filler would face significant patentability challenges.

References

1. U.S. Food and Drug Administration. (2002). Relpax (eletriptan hydrobromide) tablets: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations. FDA.